JMP Securities analyst David Turkaly reiterates Haemonetics (NYSE:HAE) with a Market Outperform and maintains $125 price target.
JMP Securities Reiterates Market Outperform on Haemonetics, Maintains $125 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.